Farkas' Departure a Positive for Sarepta (SRPT) Eteplirsen Approval - Oppenheimer
- Wall St. falls as earnings from some big names disappoint
- General Motors (GM) Tops Q3 EPS by 28c
- Procter & Gamble (PG) Tops Q1 EPS by 5c
- DuPont (DD) Tops Q3 EPS by 14c; Boosts FY16 EPS Outlook; Says Continuing to Work with Regulators
- Pre-Open Stock Movers 10/25: (SAEX) (CWEI) (SWFT) Higher; (DPRX) (CRBP) (UA) Lower (more...)
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Oppenheimer's Sarepta Therapeutic (NASDAQ: SRPT) analyst Michelle Gilson said their checks suggest that Ronald Farkas, MD, PhD, has indeed left the FDA; additionally, he is no longer listed in the HHS employee directory.
They view this as a positive signal for eteplirsen approval, recalling Dr. Farkas was the team leader who led the review of eteplirsen, and was largely regarded as an antagonistic figure at eteplirsen's advisory committee in May.
Gilson notes the DMD community and experts were particularly inflamed by comments regarding patient effort in the trial and the review's treatment of the data set as if it were not from a rare disease setting.
Contrarily, they would have viewed a promotion for Farkas or departure of a more supportive figure (i.e., Woodcock) as a negative signal for eteplirsen approval.
The firm reiterated an Outperform rating and price target of $60 on SRPT.
Shares of Sarepta Therapeutic closed at $25.60 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cantor Fitzgerald Defends Corbus Pharmaceuticals (CRBP) Following Short Report
- Sarepta Therapeutics (SRPT) Target of Cautious Article
- UBS Cuts Price Target on V.F. Corp. (VFC) to $59; Reiterates Buy
Create E-mail Alert Related CategoriesAnalyst Comments, FDA, Hot Comments, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!